The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell or hold shares. Media messages about these analysts, leased (or sale) analysts, change their ratings often affect the price of the shares. Do they really matter?
Let’s look at what these heavy weight of Wall Street should say UNITEDHEALTH GROUP (UNH) Before discussing the reliability of mediation recommendations and how to use them in your favor.
UNITEDHEALT current has an average mediation recommendation (ABR) of 1.74, on a scale of 1 to 5 (strong purchase of strong sale), calculated on the basis of actual recommendations (buy, hold, sell, etc.) made by 25 brokerage companies. ABR of 1.74 is approaching a strong purchase and purchase.
Of the 25 recommendations that extract the current ABR, 15 are strong purchases and two are purchases. The strong purchase and purchase, respectively, represents 60% and 8% of all recommendations.
Broker’s breakdown column for UNH
Verification of the price of the price and stock forecast for UNITEDHEALTH HERE >>>
ABR suggests you buy UNITEDHEALT, but making an investment decision solely based on this information may not be a good idea. According to several studies, the mediation recommendations have almost been successful in directing investors to choose shares with the highest potential for price rising.
Wondering why? The asked interest of brokerage companies in an action, which they cover, often leads to a highly positive addiction to their analysts in its assessment. Our research shows that for each recommendation for a “strong sale” brokerage companies provide five high purchases recommendations.
In other words, their interests are not always aligned with retail investors, rarely showing where the price of the action can actually be directed. Therefore, the best use of this information may be the validation of your own research or an indicator, which has proved to be extremely successful in forecasting the movement of stock prices.
Zacks Rank, our patented stock rating instrument with an impressive outwardly audited record, categorizes stock in five groups ranging from Zacks Rank #1 (strong purchase) to Zacks Rank #5 (strong sale) and is an effective indicator of stock prices in the near future. Therefore, using ABR to validate Zacks rank can be an effective way to make a winning investment decision.
Although both Zacks and ABR are displayed in a range of 1–5, they are different measures.
ABR is calculated solely on the basis of mediation recommendations and is usually displayed with decimal signs (example: 1.28). In contrast, the rank of Zacks is a quantitative model that allows investors to use the power of profit ratings. It is displayed in whole numbers – 1 to 5.
Analysts hired by brokerage companies have been and continue to be too optimistic with their recommendations. As the ratings issued by these analysts are more favorable than their research would support because of the interest of their employers, they mislead investors much more often than they lead.
On the other hand, profit ratings are at the heart of Zacks rank. And empirical research shows a strong link between trends in audits of profit values and stock prices in the short term.
In addition, the various degrees of Zacks rank are applied in proportion to all shares for which brokerage analysts provide profit forecasts for the current year. In other words, at any time, this tool maintains a balance between the five rank it assigns.
Another key difference between the rank of ABR and Zacks is freshness. ABR is not necessarily up -to -date when you look at it. But as brokerage analysts continue to review their profit ratings to account for the company’s changing business trends and their actions are reflected in the Zacks ranking quickly enough, this is always timely in indicating future prices movements.
With regard to the revisions of profit ratings for UNITEDHEALTH, the Zacks consensus prognosis for the current year decreased by 4.2% in the last month to $ 21.15.
The increasing pessimism of analysts over the company’s profit prospects, as stated by a strong agreement between them in the review of EPS more, may be a valid reason for the shares to immerse themselves in the near future.
The size of the recent change in the evaluation of the consensus, along with three other factors related to profit ratings, has led to Zacks Rank #4 (Sell) for UNITEDHEALT. You can see the full list of today’s Zacks Rank #1 (Strong Buy) here >>>>
Therefore, it may be reasonable to take the equivalent of the purchase of an abba for Unitedhealth with grain salt.
Do you want the latest recommendations from Zacks Investment Research? Today you can download 7 best shares for the next 30 days. Click to get this free report
UNITEDHEALTH GROUP INCORPORATED (UNH): FREE stock analysis Report
This article originally published for Zacks Investment Research (Zacks.com).
